Skip to content
Atorvia logo

About us

Atorvia is early-stage biotech on a mission to end organ failure. With a key focus on proteomics, and assisted by machine learning tools, Atorvia is developing novel treatments targeting the regulated cell death pathway that causes organ failure.

Atorvia’s first therapeutic is at the lead identification stage with a first indication in kidney to prevent and treat Acute Kidney Injury – a common complication that occurs in tens of millions of patients each year and which currently lack treatment options. Many of these patients require dialysis and experience long-term health complications such as heart disease and diabetes – even from a single, temporary episode of kidney failure.

Atorvia is on a mission to end this.

Program engagement

Leadership

Mridul Nair

Director Translational & Clinical Development

Status

Intellectual Property

Fundraising

Sector

Subsector

The Big DiF Innovation Factory's 15th Annual Open House on May 1 2025 from 4pm - 8pm

Join Innovation Factory's Annual Open House - The Big DiF!

Network with 300+ industry professionals, discover emerging solutions from our innovators, and celebrate entrepreneurship within the Hamilton-Halton ecosystem.

May 1, 2025 | 4:00pm – 8:00pm | Hamilton, Ontario